Кишечника: пути патогенеза и вопросы выбора генно-инженерных препаратов

Larisa S. Kruglova – MD, PhD, Professor, Head of the 
Chair of Dermatovenereology and Cosmetology
1
; 
ORCID: http://orcid.org/ 0000-0002-5044-5265
*
19/1A Marshala Timoshenko ul., Moscow, 
121359, Russian Federation. Tel.: +7 (916) 705 69 07.
E-mail: kruglovals@mail.ru
Andrey N. Lvov – MD, PhD, Professor, Head of the 
Department of Clinical Dermatovenereology and 
Cosmetology
2
; ORCID: https://orcid.org/0000-0002-
3875-4030. E-mail: alvov@mail.ru
Anna V. Kagramanova – MD, PhD, Senior Research 
Fellow, Department of Inflammatory Bowel 
Diseases
3
. E-mail: a.kagramanova@mknc.ru
Oleg V. Knyazev – MD, PhD, Head of the 
Department of Inflammatory Bowel Diseases
3
. 
E-mail: o.knyazev@mknc.ru
L.S. Kruglova
1
• A.N. Lvov
2
• A.V. Kagramanova
3
• O.V. Knyazev
3
Conflict of interests
L.S. Kruglova has received lecture and consultancy fees from Janssen Pharmaceutica Johnson & Johnson, Novartis, Pfizer, 
La Roche Posay, Pierre Fabre, Uriage, Jadran JGL, Glenmark, Meda, Bayer Healthcare, Galderma, Sanofi, USB, LEO Pharma. 
A.N. Lvov has received lecture and consultancy fees from Janssen Pharmaceutica Johnson & Johnson, Novartis, Pfizer, 
La Roche Posay, Pierre Fabre, Uriage, Jadran JGL, Glenmark, Meda, Bayer Healthcare, Galderma, Sanofi, USB, LEO Pharma. 
A.V. Kagramanova has received lecture and consultancy fees from Takeda, Pfizer, Novomedica. O.V. Knyazev has received 
lecture and consultancy fees from Takeda, Pfizer, Novomedica.
Authors' contributions
L.S. Kruglova, the paper concept and design, literature search and analysis, data management, text writing and editing, 
final approval of the manuscript; A.N. Lvov, A.V. Kagramanova and O.V. Knyazev, the paper concept and design, literature 
search and analysis, data management, text writing and editing. All the authors have contributed significantly to the study 
conduct and preparation of the paper, have read and approved its final version before the publication.
Psoriasis and inflammatory bowel diseases: 
pathogenetic pathways and the choice of 
biologic therapy (a literature review)
in Crohn's disease and rheumatoid arthritis. 
Aliment Pharmacol Ther. 2017;45(8): 1058–72. 
doi: 10.1111/apt.13995.
41. Kim BS, Lee WK, Pak K, Han J, Kim GW, Kim HS, 
Ko HC, Kim MB, Kim SJ. Ustekinumab treat-
ment is associated with decreased systemic 
and vascular inflammation in patients with 
moderate-to-severe psoriasis: Feasibility 
study using 18F-fluorodeoxyglucose PET/CT. 
J Am Acad Dermatol. 2019;80(5): 1322–31. doi: 
10.1016/j.jaad.2018.03.011.
42. Hindryckx P, Novak G, Bonovas S, Peyrin-Bir-
oulet L, Danese S. Infection Risk With Biologic 
Therapy in Patients With Inflammatory Bowel 
Disease. Clin Pharmacol Ther. 2017;102(4): 
633–41. doi: 10.1002/cpt.791.
43. Weizman AV, Nguyen GC, Seow CH, Targown-
ik L, Murthy SK, Boland K, Afzal NM, Khanna R, 
Jones J, Afif W, Halder S, Reinglas J, Fowler S, 
Huang V, Kaplan GG, Melmed GY. Appropri-
ateness of Biologics in the Management of 
Crohn's Disease Using RAND/UCLA Appro-
priateness Methodology. Inflamm Bowel Dis. 
2019;25(2): 328–35. doi: 10.1093/ibd/izy333.
Almanac of Clinical Medicine. 2019; 47 (6): 568–578. doi: 10.18786/2072-0505-2019-47-062
578